Alex Schepart

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 7

Top Topics

Multiple Myeloma

Clinical Decision Support

Top Venues

Future oncology (London, England)

Leukemia & lymphoma

This page only lists publications with an associated author ORCID identifier.

Publications

Luciano José Megale Costa, Thomas William LeBlanc, Hans Tesch, Pieter Sonneveld, Ryan P Kyle, Liliya Sinyavskaya, Patrick Hlavacek, Aster Meche, Jinma Ren, Alex Schepart, Didem Aydin, Guido Nador, Marco daCosta DiBonaventura
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma. Future oncology (London, England) (2024)
Isha Mol, Yannan Hu, Thomas William LeBlanc, Joseph C Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Alex Schepart, Patrick Hlavacek
A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma. Leukemia & lymphoma (2024)
Luciano José Megale Costa, Thomas William LeBlanc, Hans Tesch, Pieter Sonneveld, Ryan P Kyle, Liliya Sinyavskaya, Patrick Hlavacek, Aster Meche, Jinma Ren, Alex Schepart, Didem Aydin, Guido Nador, Marco daCosta DiBonaventura
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma. Future oncology (London, England) 20 (17) (2024)
Isha Mol, Yannan Hu, Thomas William LeBlanc, Joseph C Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Alex Schepart, Patrick Hlavacek
A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma. Leukemia & lymphoma 65 (5) (2024)
Luciano José Megale Costa, Thomas William LeBlanc, Hans Tesch, Pieter Sonneveld, Ryan P Kyle, Liliya Sinyavskaya, Patrick Hlavacek, Aster Meche, Jinma Ren, Alex Schepart, Didem Aydin, Guido Nador, Marco daCosta DiBonaventura
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma. Future oncology (London, England) (2024)
Luciano José Megale Costa, Thomas William LeBlanc, Hans Tesch, Pieter Sonneveld, Ryan P Kyle, Liliya Sinyavskaya, Patrick Hlavacek, Aster Meche, Jinma Ren, Alex Schepart, Didem Aydin, Guido Nador, Marco daCosta DiBonaventura
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma. Future oncology (London, England) 20 (17) (2024)
Luciano José Megale Costa, Thomas William LeBlanc, Hans Tesch, Pieter Sonneveld, Ryan P Kyle, Liliya Sinyavskaya, Patrick Hlavacek, Aster Meche, Jinma Ren, Alex Schepart, Didem Aydin, Guido Nador, Marco daCosta DiBonaventura
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma. Future oncology (London, England) 20 (17) (2024)